BioValleyCHINA Ventures
Global BioTechnology Incubation
 Western Management and Funding in China Medical Parks


Facilitated "spin-out" technology from BioSante Pharmaceuticals, Inc. and co-Founded Cold Genesys, Inc.

 LINCOLNSHIRE, Illinois (November 17, 2010) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer.

Cold Genesys, Inc is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment with a present emphasis on bladder cancer. Based in Newport Beach, California, Cold Genesys is a privately funded, early-stage company anticipating global development of its technology.
Website Builder